ACR Appropriateness Criteria Follow-Up of Malignant or Aggressive Musculoskeletal Tumors

Catherine C. Roberts, Mark J. Kransdorf, Francesca D. Beaman, Ronald S. Adler, Behrang Amini, Marc Appel, Stephanie Bernard, Ian Blair Fries, Isabelle M. Germano, Bennett S. Greenspan, Langston T. Holly, Charlotte D. Kubicky, Simon Shek-Man Lo, Timothy Mosher, Andrew E. Sloan, Michael J. Tuite, Eric Walker, Robert J. Ward, Daniel E. Wessell, Barbara N. Weissman

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Appropriate imaging modalities for the follow-up of malignant or aggressive musculoskeletal tumors include radiography, MRI, CT, 18F-2-fluoro-2-deoxy-D-glucose PET/CT, 99mTc bone scan, and ultrasound. Clinical scenarios reviewed include evaluation for metastatic disease to the lung in low- and high-risk patients, for osseous metastatic disease in asymptomatic and symptomatic patients, for local recurrence of osseous tumors with and without significant hardware present, and for local recurrence of soft tissue tumors. The timing for follow-up of pulmonary metastasis surveillance is also reviewed. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)389-400
Number of pages12
JournalJournal of the American College of Radiology
Issue number4
StatePublished - Apr 1 2016

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'ACR Appropriateness Criteria Follow-Up of Malignant or Aggressive Musculoskeletal Tumors'. Together they form a unique fingerprint.

Cite this